Business Insights, June 2009, Pages: 147
Emerging Clinical Trial Locations – Eastern Europe: Market Dynamics andthe Changing Healthcare and Regulatory Environment Over the last decade pharmaceuticaland biotechnology companies have entered
Jain PharmaBiotech, June 2012, Pages: 1045
taken place intheUnited States, which has the largest number of companies.
Themarketsfor molecular diagnostics technologies are difficult to estimate. Molecular diagnostics markets overlap with
Jain PharmaBiotech, June 2012, Pages: 809
/biopharmaceuticals industry for several years. He received graduate training in both EuropeandUSA, has held academic positions in several countries and is a Fellow of the Faculty of Pharmaceutical Medicine of the
TriMark Publications, April 2009, Pages: 320
2.6.1.2 Asia-Pacific to Replace United StatesandEurope as Pharmaceutical Industry Center 54
2.6.1.3 The Changing Pharmaceutical Business Model 54
2.6.2 Benefits for Companion Diagnostic Tests in Drug
Marketstrat Inc, April 2009, Pages: 457
for Infusion Pumps inU.S. dollars.
Product/Market Segment Analysis and Forecasts by Region (2008-2015)
Market Data: Unit sales, ASPs and Revenues Estimates/Forecasts for 2008-2015 inUS dollars by
Marketstrat Inc, Aug 2008, Pages: 528
)
Market estimates and forecasts for Sleep Apnea Diagnostic and Therapeutic Devices by country/region (Units andUS $, 2006 – 2014) for: USA
Canada & Latin America; Europe; Japan; and Rest of the World
Espicom Business Intelligence Ltd, Aug 2008, Pages: 352
inthe UK are all assessing new cancer biomarkers and technology platforms for biomarker discovery and validation.
Questions, Questions
What will the global cancer biomarker market be worth in 2015
ICON Group International, June 2007, Pages: 383
representative office in Lithuania gives the foreign company a legal presence inthe country, but does not permit it to carry on any economic activity, and is thus useful only forassessing business opportunities
